Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint and KSQ-Lung as key secondary endpoint. On track to complete enrollment in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD in the first half of 2026. Ended the first quarter 2026 with $68.3 million in cash, cash equivalents, restricted cash and investments. SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform,...

Company Advances Portfolio Streamlining Strategy, Including Proposed Sale of CMD in Potential $65 Million All-Cash Transaction Operating Expenses from Continuing Operations Declined Approximately 53%; Loss from Operations Improved Approximately 44%; Achieved Positive Cash Flow From Operations NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) — 1847 Holdings LLC (OTC: LBRA) (“1847 Holdings” or the “Company”), a diversified acquisition holding company focused on identifying and monetizing overlooked, deep-value businesses, today announced financial results for the first quarter ended March 31, 2026. During the first quarter of 2026, the Company’s Board of Directors approved a plan to actively market for sale of CMD Inc. (“CMD”), which comprises the CMD segment within the Company’s Construction operations. As a result, CMD has been classified...

NORCROSS, Ga., May 15, 2026 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2026. “We continue to make meaningful progress advancing the belapectin program and further analyzing the NAVIGATE dataset in patients with MASH cirrhosis and portal hypertension. The additional analyses, including biomarker data, continue to support the potential of belapectin to impact disease progression in this high-risk population. We are looking forward to our upcoming data presentations at EASL later this month and our in-person Type-C meeting with FDA this quarter. Additionally, we remain focused on engaging with potential partners and leading experts to help determine...

Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6.5 million in cash and promising Protein Oral Delivery™ biomed technology, with lead asset ORMD-0801 oral insulin set to commence Phase 2 study Acquired upper body exoskeleton technology addressing unmet need in 4.6 million stroke survivors Quarterly operating cash burn reduced by 33% year-over-year, reflecting improved operational efficiencies and working capital management Continued improvements in operating expenses and cash utilization as company prepares to scale neurorehabilitation products volume Conference call scheduled for 8:30 AM ET today HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 15, 2026 (GLOBE NEWSWIRE) — Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation...

Strategic First Quarter Investments Lay Foundation for Long-Term Growth NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) — Our Bond, Inc. (“Bond”) (NASDAQ: OBAI), the creator of the world’s first AI-powered Preventative Personal Security platform adopted by leading multinational companies, today provided a business update and reported financial results for the first quarter of 2026 ended March 31, 2026. Business HighlightsStrong Enterprise Demand: Continued strong demand from enterprise customers, with deployments expanding across retail, telecommunications, financial services, pharmaceuticals and multinational organizations. Global Expansion: Expanded global footprint, with operations now spanning multiple regions, countries and languages. Multi-Channel Growth Strategy: Continued execution of Bond’s multi-channel go-to-market strategy...

SUNNYVALE, Calif., May 15, 2026 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter 2026 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2026 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management’s formal remarks, there will be a question-and-answer session. Recent Business Highlights CardiAMP® autologous cell therapy in ischemic heart failure of reduced ejection fraction (BCDA-01)In February, PMDA provided additional questions for BioCardia, in line with those addressed and discussed in three preliminary...

OAKLAND, Calif., May 15, 2026 (GLOBE NEWSWIRE) — ContextLogic Holdings Inc. (OTCQB: LOGC) (“ContextLogic,” the “Company,” “we” or “our”) today reported its financial results for the first quarter ended March 31, 2026. Basis of Presentation  ContextLogic completed the acquisition of US Salt on February 26, 2026. To reflect the basis difference as a result of the US Salt acquisition, GAAP results for the first quarter of 2026 are presented in two parts: the period from January 1, 2026 through February 26, 2026 (“Predecessor”), reflecting legacy US Salt, and the period from February 27, 2026 through March 31, 2026 (“Successor”), reflecting ContextLogic Holdings Inc. and US Salt on a consolidated basis. To provide comparable period-over-period information, the Company also presents “Combined” results, a non-GAAP measure that aggregates...

Bayport Management Ltd Q1 2026 Financial StatementsAttachmentsGroup Quarterly report_March 2026Group Quarterly report_March 2026

Bayport Intermediate Holdco PLC Q1 2026 Financial StatementsAttachmentQuarterly report IH PLC_March 2026

Increased Government Sales Pipeline Driving Momentum Following Successful U.S. Army Exercises and Demonstrations in Q1 AVENTURA, Fla., May 15, 2026 (GLOBE NEWSWIRE) — Safe Pro Group Inc. (Nasdaq: SPAI) (Safe Pro or the Company), a developer of artificial intelligence (AI)-enabled defense, security, and situational awareness solutions, today announced financial results for the quarter ended March 31, 2026 reflecting the significant impact of a recently commercialized AI-powered Edge compute solution subcontract. First Quarter 2026 Financial and Recent Operational Highlights Include:Record Revenue Growth and High Margins Driven by AI Product SalesRecord quarterly revenue of $1,220,129 represents a 560% increase over $184,802 reported in the first quarter of 2025. Safe Pro AI quarterly revenue surged over 2,400%, driven by new...